Menu
← Oncology Approval Tracker
FDA DECISION ·
Gavreto
pralsetinib · Blueprint Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children ages 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy.
LAMPGEN ANALYSIS
Why it matters
Extended selective RET inhibition to a RET-mutant medullary thyroid cancer population under accelerated approval; FDA later withdrew this indication.
What research teams should watch
Record the mutation and medullary histology, and check the status of this specific indication before using the archive in a current summary.
PRIMARY RECORDS